Literature DB >> 6794954

An improved fluorometric leukocyte beta-glucosidase assay for Gaucher's disease.

L B Daniels, R H Glew, W F Diven, R E Lee, N S Radin.   

Abstract

Three fluorometric leukocyte beta -glucosidase assays were compared for their ability to diagnose Gaucher's disease and identify carriers of the disorder: the acid beta-glucosidase assay of Beutler and Kuhl [2], a pH 5.5-sodium taurocholate-dependent assay and a new procedure which employs conduritol B epoxide, an active-site specific inhibitor of glucocerebrosidase. All three assays unambiguously identified patients with Gaucher's disease. With regard to identifying carriers the bile salt dependent assay of Peters et al. and the conduritol B epoxide-dependent procedure gave the greatest discrimination between the mean beta-glucosidase values for the control and heterozygote samples when evaluated using Student's t test. The most reliable assay for the identification of the carrier state was the conduritol B epoxide-dependent procedure which can be expected to provide the fewest false negative results when classifying heterozygotes (5%). However, the fact that none of these methods will completely separate control and heterozygote samples indicates that their use in screening programs will result in a significant number of incorrect assignments.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6794954     DOI: 10.1016/0009-8981(81)90251-5

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  9 in total

1.  External quality assurance programme for enzymatic analysis of lysosomal storage diseases: a pilot study.

Authors:  G J G Ruijter; M Boer; C W Weykamp; R de Vries; I van den Berg; J Janssens-Puister; K Niezen-Koning; R A Wevers; B J H M Poorthuis; O P van Diggelen
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Role of chitotriosidase (chitinase 1) under normal and disease conditions.

Authors:  Manasa Kanneganti; Alan Kamba; Emiko Mizoguchi
Journal:  J Epithel Biol Pharmacol       Date:  2012

3.  GBA mutations in Gaucher type I Venezuelan patients: ethnic origins and frequencies.

Authors:  Gilberto Gómez; Sergio Arias; Leonor Cárdenas; Dalal Zoghbi; Irene Paradisi
Journal:  J Genet       Date:  2017-09       Impact factor: 1.166

4.  The Arabidopsis AtGCD3 protein is a glucosylceramidase that preferentially hydrolyzes long-acyl-chain glucosylceramides.

Authors:  Guang-Yi Dai; Jian Yin; Kai-En Li; Ding-Kang Chen; Zhe Liu; Fang-Cheng Bi; Chan Rong; Nan Yao
Journal:  J Biol Chem       Date:  2019-12-08       Impact factor: 5.157

5.  β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology.

Authors:  Christina M Ridley; Karen E Thur; Jessica Shanahan; Nagendra Babu Thillaiappan; Ann Shen; Karly Uhl; Charlotte M Walden; Ahad A Rahim; Simon N Waddington; Frances M Platt; Aarnoud C van der Spoel
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

6.  Acute Gaucher Disease-Like Condition in an Indian Infant with a Novel Biallelic Mutation in the Prosaposin Gene.

Authors:  Akella Radha Rama Devi; Srilatha Kadali; Ananthaneni Radhika; Vineeta Singh; M Aravind Kumar; Gummadi Maheshwar Reddy; Shaik Mohammad Naushad
Journal:  J Pediatr Genet       Date:  2018-10-26

7.  Characterization of the phospholipid requirement of a rat liver beta-glucosidase.

Authors:  A Basu; R H Glew
Journal:  Biochem J       Date:  1984-12-01       Impact factor: 3.857

8.  High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase.

Authors:  Ehud Goldin; Wei Zheng; Omid Motabar; Noel Southall; Jae Hyuk Choi; Juan Marugan; Christopher P Austin; Ellen Sidransky
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

9.  Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease.

Authors:  Mylene Huebecker; Elizabeth B Moloney; Aarnoud C van der Spoel; David A Priestman; Ole Isacson; Penelope J Hallett; Frances M Platt
Journal:  Mol Neurodegener       Date:  2019-11-08       Impact factor: 14.195

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.